Page 47 - Read Online

Nasr et al. Metab Target Organ Damage 2023;3:19 https://dx.doi.org/10.20517/mtod.2023.20 Page 13 of 17

52. Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty
liver disease. Liver Int 2014;34:129-35. DOI PubMed
53. Cao G, Yi T, Liu Q, Wang M, Tang S. Alcohol consumption and risk of fatty liver disease: a meta-analysis. PeerJ 2016;4:e2633.
DOI PubMed PMC
54. Moriya A, Iwasaki Y, Ohguchi S, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol 2015;62:921-7.
DOI
55. Hagström H, Nasr P, Ekstedt M, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of
fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2017;52:159-65. DOI
56. Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a
national prospective cohort study. Hepatology 2019;70:511-21. DOI PubMed PMC
57. Ekstedt M, Franzén LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic
fatty liver disease. Scand J Gastroenterol 2009;44:366-74. DOI
58. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma
in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8. DOI PubMed
59. Ajmera V, Belt P, Wilson LA, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Among patients with nonalcoholic fatty
liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol
Hepatol 2018;16:1511-1520.e5. DOI PubMed PMC
60. Kimura T, Tanaka N, Fujimori N, et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver
disease with advanced fibrosis. World J Gastroenterol 2018;24:1440-50. DOI PubMed PMC
61. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular
disease outcomes: a systematic review and meta-analysis. BMJ 2011;342:d671. DOI PubMed PMC
62. 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global
burden of disease study 2016. Lancet 2018;392:1015-35. DOI PubMed PMC
63. Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in
predicting severe liver disease in the general population. Hepatology 2018;67:2141-9. DOI PubMed
64. Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver
disease: a cohort study. Hepatology 2019;69:64-75. DOI
65. Younossi ZM, Stepanova M, Ong J, et al; Global NASH Council. Effects of alcohol consumption and metabolic syndrome on
mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol 2019;17:1625-1633.e1.
DOI
66. Hagström H, Ekstedt M. Considerations in the search for under-reported alcohol consumption in NAFLD. J Hepatol 2023;78:e66-7.
DOI PubMed
67. Ezhilarasan D. Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms. Toxicology
2021;458:152840. DOI PubMed
68. Malaviya AN, Sharma A, Agarwal D, Kapoor S, Garg S, Sawhney S. Low-dose and high-dose methotrexate are two different drugs
in practical terms. Int J Rheum Dis 2010;13:288-93. DOI PubMed
69. Roenigk HH, Fowler-Bergfeld W, Curtis GH. Methotrexate for psoriasis in weekly oral doses. Arch Dermatol 1969;99:86-93.
PubMed
70. Sundbaum J, Eriksson N, Hallberg P, Lehto N, Wadelius M, Baecklund E. Methotrexate treatment in rheumatoid arthritis and
elevated liver enzymes: a long-term follow-up of predictors, surveillance, and outcome in clinical practice. Int J Rheum Dis
2019;22:1226-32. DOI PubMed PMC
71. Schröder T, Schmidt KJ, Olsen V, et al. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease
under immunosuppressive treatment. Eur J Gastroenterol Hepatol 2015;27:698-704. DOI
72. Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid
arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. DOI PubMed
PMC
73. Chalmers RJ, Boffa MJ, Kirby B, Smith A. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol
2001;44:879-80. DOI PubMed
74. Zachariae H, Kragballe K, Søgaard H. Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued
treatment. Br J Dermatol 1980;102:407-12. DOI PubMed
75. Zachariae H, Søgaard H, Heickendorff L. Methotrexate-induced liver cirrhosis. clinical, histological and serological studies--a further
10-year follow-up. Dermatology 1996;192:343-6. DOI PubMed
76. Zachariae H, Schiodt T. Liver biopsy in methotrexate treatment. Acta Derm Venereol 1971;51:215-20. DOI PubMed
77. Gelfand JM, Wan J, Zhang H, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis
receiving methotrexate: a population-based study. J Am Acad Dermatol 2021;84:1636-43. DOI
78. Ruan Z, Lu T, Chen Y, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA
Dermatol 2022;158:745-53. DOI PubMed PMC
79. Maybury CM, Porter HF, Kloczko E, et al. Prevalence of advanced liver fibrosis in patients with severe psoriasis. JAMA Dermatol
2019;155:1028-32. DOI PubMed PMC